Sysnav Healthcare and Roche unite to collect real-world data using movement tracking technology to improve outcomes for people with movement disorders

The two companies will leverage Sysnav’s proprietary movement tracking technology to develop new regulatory-fit digital outcome measures for patients with movement disorders to monitor disease progression, support clinical studies, and develop new technologies.

French tech company Sysnav Healthcare has announced they are forming a multi-year partnership with Roche to use real-world data (RWD) collected via wearable, motion-capture biosensor technology to improve the outcomes for people with neuromuscular and other movement-associated disorders. Sysnav’s proprietary technology captures patients’ motor functions to help identify and track neurological and neuromuscular pathology patterns. Using the collected RWD, clinicians and researchers can interpret and analyze these neurological changes to develop new fit-for-purpose, regulatory-grade digital endpoints to measure outcomes for people with motor impairments as well as advance clinical research, drug development and newer technologies.

James Sabry, Global Head of Roche Pharma Partnering commented “Sysnav’s technology offers the opportunity to measure functional disease progression to a regulatory standard across a range of diseases. This has the potential to improve the way patients are involved in clinical studies, the ability to determine potential treatment benefits, and enrich our understanding of disease pathophysiology”.

Sysnav’s magneto-inertial technology enables precise motion capture without the need for GPS movement tracking, offering protection of patient privacy. The technology has already been utilized in two wearable devices: ActiMyo for use in clinical trials and the next generation Syde. Both utilize SV95C, the first-ever digital endpoint qualified by the European Medicines Agency. SV95c, or stride velocity 95th percentile, is a measure of the top walking speed of patients at home and is used as a secondary clinical outcomes assessment for use in pivotal and exploratory clinical trials for Duchenne’s muscular dystrophy.

“Bringing together Sysnav’s digital health technology and Roche’s expertise in neuroscience drug development and personalized healthcare will enable us to have a truly meaningful impact on patients with motor impairments” said says Damien Eggenspieler, Sysnav Healthcare Program Director. “By establishing a new set of industry standards for the evaluation of motor impairments, we can unlock innovation for the benefit of all patients,” Eggenspieler added.